Improved peptide manufacturing process of etelcalcetide, the active ingredient in, Parsabiv™— a drug for the treatment of secondary hyperparathyroidism in adult patients with chronic kidney disease. This novel process reduces chemical solvent use by 71%, manufacturing operating time by 56%, and manufacturing costs by 76%. This could eliminate over 14,400 cubic meters of waste, including 750 cubic meters of aqueous waste, while increasing profits. Peptide drugs have high specificity and affinity and superior safety and tolerance, making them more desirable than small molecule drugs in cancer, enzyme deficiency disorders, protein-dysfunction disorders, genetic and degenerative diseases, and infectious diseases. Generally peptide production requires much more solvent than that of small molecules.
EPA Green Chemistry Challenge: 2017 Greener Reaction Conditions Award
in cooperation with Bachem Holding
